Jinwon Life Sciences VGXI Officially Invited to Participate in the 'JP Morgan Healthcare Conference'

Jinwon Life Sciences announced on the 4th that its subsidiary VGXI has been officially invited to participate in the 42nd J.P. Morgan Healthcare Conference, held in San Francisco, USA, from the 8th to the 11th local time, for the third consecutive year.

Started in 1983, the J.P. Morgan Healthcare Conference is the world's largest pharmaceutical and biotechnology event hosted by the global investment bank J.P. Morgan Chase, gathering healthcare companies worldwide as well as venture capital and private equity investment firms.

Park Young-geun, CEO of Jinwon Life Sciences, stated, "Through participation in this event, we plan to focus on promoting VGXI's high-quality plasmid DNA contract development and manufacturing organization (CDMO) competitiveness and expanding partnerships." He added, "The sales team led by Chief Commercial Officer (CCO) Jeff Whitmore will do their best to promote VGXI's excellent production capabilities and differentiated high-quality product manufacturing services to potential clients and investors, aiming to achieve tangible sales results."